{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:43:51Z","timestamp":1783035831170,"version":"3.54.6"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1136\/ard-2022-223044","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:20:19Z","timestamp":1668104419000},"page":"164-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02807103","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04157348","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05263934","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-921X","authenticated-orcid":false,"given":"Alvise","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-3148","authenticated-orcid":false,"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-9172","authenticated-orcid":false,"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223044_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223044_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus Task force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1136\/ard-2022-223044_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223044_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223044_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2019.11.045","article-title":"Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity","volume":"157","author":"Berti","year":"2020","journal-title":"Chest"},{"key":"10.1136\/ard-2022-223044_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","article-title":"The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions","volume":"3","author":"Lombardi","year":"2022","journal-title":"Curr Res Immunol"},{"key":"10.1136\/ard-2022-223044_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"key":"10.1136\/ard-2022-223044_bib8","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223044_bib9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","article-title":"Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223044_bib10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1136\/ard-2022-223044_bib11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1136\/ard-2022-223044_bib12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223044_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2022-223044_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-Term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the Bora phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2022-223044_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-Interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1136\/ard-2022-223044_bib16","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2022-223044_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223044_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223044_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clicom.2022.01.002","article-title":"Real-Life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"2","author":"Ramirez","year":"2022","journal-title":"Clinical Immunology Communications"},{"key":"10.1136\/ard-2022-223044_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejim.2021.08.021","article-title":"Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis","volume":"95","author":"R\u00edos-Garc\u00e9s","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1136\/ard-2022-223044_bib21","doi-asserted-by":"crossref","first-page":"00451-2020","DOI":"10.1183\/23120541.00451-2020","article-title":"Steroid-Sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Nanzer","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1136\/ard-2022-223044_bib22","first-page":"101050","article-title":"Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis","volume":"30","author":"Coppola","year":"2020","journal-title":"Respir Med Case Reports"},{"key":"10.1136\/ard-2022-223044_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.18176\/jiaci.0689","article-title":"Benralizumab: resolution of eosinophilic pulmonary vasculitis in a patient with EGPA","volume":"31","author":"Bormioli","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1136\/ard-2022-223044_bib24","doi-asserted-by":"crossref","first-page":"00311","DOI":"10.1183\/23120541.00311-2019","article-title":"Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Kent","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1136\/ard-2022-223044_bib25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2020.09.025","article-title":"Mepolizumab 100 Mg in severe asthmatic patients with EGPA in remission phase","volume":"9","author":"Caminati","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1136\/ard-2022-223044_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-021-02462-6","article-title":"Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis","volume":"23","author":"Ueno","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223044_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roab005","article-title":"Low-Dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis","volume":"32","author":"Nakamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223044_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-Life evidence of low-dose mepolizumab efficacy in EGPA: a case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir Res"},{"key":"10.1136\/ard-2022-223044_bib30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4168\/aair.2020.12.5.885","article-title":"Low-Dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Vultaggio","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1136\/ard-2022-223044_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","volume":"16","author":"Cottin","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223044_bib32","first-page":"S41-7","article-title":"Anca-Positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center","volume":"32","author":"Sokolowska","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223044_bib33","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-Wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-223044_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223044_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr2.11263","article-title":"Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America","volume":"3","author":"Doubelt","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223044_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.07.017","article-title":"Severe\/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis","volume":"142","author":"Berti","year":"2018","journal-title":"Respir Med"},{"key":"10.1136\/ard-2022-223044_bib37","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223044_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223044_bib39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223044_bib40","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672408573X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672408573X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T23:29:46Z","timestamp":1737242986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672408573X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S000349672408573X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223044","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}